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We investigated a 6-year-old boy who developed fatal CMV and Epstein-Barr virus (EBV) diseases 3 months (M3) following CBT and compared him with children viral controls (median age: 6 years) after CBT (n = 14), and BMT (n = 6), who were investigated at the same time after transplantation (day (D) 83 vs mean D101 (88-111)) and with healthy volunteers (HV). Our patient underwent a myeloablative conditioning regimen, which includes i.v. rabbit anti-thymocyte globulin (2.5 mg/kg/D, 3 days, Imtix- Sangstat, Lyon, France) as all CB controls, TBI 12 gray (as half of CB controls) and CY. GVHD prophylaxis consisted in CYA and corticosteroids for all CB recipients.
Our patient underwent a 5/6 HLA-matched CBT for an acute leukemia in a second complete state remission. Chimerism in total nucleated cells reached 497% of the donor's by D60 and 93% of the donor's by D83. He did not develop GHVD. Figure 1a illustrates the values of EBV DNA viral load and CMV antigenemia from transplantation to death. The CMV disease was assessed by respiratory distress, the EBV disease was assessed by severe clinical manifestations, that is, fever, lymphoadenopathies, parotitis and respiratory distress. CMV infection was treated by i.v. Foscarnet, then i.v. Ganciclovir and EBV infection by anti-CD20 therapy (Rituximab 375 mg/m 2 per week repeated three times). Despite the negativation of CMV antigenemia and EBV DNA viral load in peripheral blood, the patient's clinical condition worsened, resulting in respiratory failure. Death occurred on D92 post CBT from acute respiratory distress syndrome directly related to EBV and CMV disease (positive CMV PCR in bronchial tissue (D85), positive EBV PCR in bronchial fluids).
Our patient exhibited a profound and prolonged deficiency of CD4+ (o 20/mm 3 ), NK (o 160/mm 3 ) and γδ T cells (o 100/mm 3 ) between D60 and D83, but had a markedly increased CD8+ T-cell count ranging from 54/mm 3 to 1 058/mm 3 , which resulted in a collapsed CD4:CD8 ratio at D83 (CD4:CD8 ratio = 0.01 vs median 0.7 ± 1.3% for CB controls; n = 11). CD8+ T cells were mostly in the effector memory (EM) stage of differentiation (CD45RA − CD27 − ) with almost no naive cells at D83 (Figure 1b) . CD8+ T cells were highly activated, as illustrated by their significantly higher expression, as compared with CB controls, of HLA-DR (percentage 40 vs 26%; MFI 2 905 vs median 168 ± 39%, n = 7), CD572 (percentage 81 vs 26%; MFI 13 447 vs median 603 ± 328%, n = 6), CD69 (MFI 1 502 vs median 336 ± 75%, n = 6) and expressed perforin (22% vs median 29 ± 6%, n = 13). PD-1 was overexpressed on CD8+ T cells with a percentage of expression of 99% vs 39 ± 3% for healthy volunteer (n = 4) and 74 ± 2.6% for CB controls (n = 7). CD8+ T cells EBV CTL (BZLF1 pentamer-positive RAKFQLL) were detected and represented up to 12% of the total CD8+ T cells (Figure 1c ). These cells were mainly differentiated in the EM stage, with no naive or TEMRA cells (CD45RA+CD27 − ), were activated, as demonstrated by their high level of expression of HLA-DR, and overexpressed PD-1 (Figure 1d ). An ELISPOT IFNγ assay was performed to investigate if, despite an overexpression of PD-1, virus-specific CD8 T cells were able to secrete IFN-γ in the presence of an EBV pool. The patient had a positive marked response to the EBV pool at D83 (Figure 1e ), conversely to all CB (n = 11) and BM (n = 5) recipients tested at the same time after CBT (M3) who had a negative response. In addition, the patient had CMV CTL in low quantity that were differentiated in an EM stage, with no naive or TEMRA cells, and that overexpressed the PD-1 inhibitory receptor (data not shown). As concern innate immune system, γδ T cells were also activated, as illustrated by their high percentage of expression of CD57 and CD69 (Figure 2a) . NK cells were quantitatively deficient (ALC = 160/mm 3 vs mean 530/mm 3 (160-1450) for CB controls, n = 11) and had a skewed pattern of differentiation (Figure 2b) . Indeed, NK cells had a higher proportion of the CD56 bright CD16 − subset and a lower proportion of the CD56 dim CD16 + subset as compared with CB controls at M3. The CD56 − CD16 − subset accounted for 56% of CD3 − CD56 − CD19 − NK cells vs median of 30% in CB controls (n = 9). CD56 − CD16 − cells appeared to be NK cells as they expressed NKp46, as well as NKp30 NCR. They also appeared to have a potential cytotoxic capacity, as they expressed the NKG2C receptor (Figure 2c) . The patient's NK cells exhibited a higher level of expression of NKp30 and NKG2A and slightly lower levels of expression of NKG2C than NK cells from CB controls (Figure 2c) .
DISCUSSION
This patient who underwent both CMV and EBV disease exhibited a profound lymphocyte quantitative deficiency, especially in CD4+ T cells. Nevertheless, he exhibited virusspecific CTL that were activated. To our knowledge, this is the first documented evidence of such an important virus CTL recovery within the first 100 days after CBT. Nevertheless, as donor chimerism went down to 93% of total nuclear cells, participation of the patient's self CD8+ T cells in EBV surveillance cannot be excluded.
Thus, the results of this patient showed evidence of immune exhaustion. As shown in murine models, our patient exhibited the following: (1) persistence of a high level of viral antigens (Figure 1a) , (2) significant T-cell activation (high DR, CD69, CD57 and perforin expression), (3) an altered pattern of differentiation (poor naive and CM cells regeneration), (4) low CD4+ cell number (o 20/mm 3 , which resulted in a strikingly altered CD4:CD8 ratio) and (5) an overexpression of PD-1 inhibitor receptor (in total CD8+ T cells and virus-CTL 2, 3 ). In addition, NK cells were deficient, highly activated, upregulated the NKG2A inhibitory receptor and presented an atypical pattern of differentiation. In this setting of CMV disease, the maintenance of a markedly low NK-cell count, the downregulation of CD16 and the high level of expression of NKG2A may all be hallmarks of a mechanism for viral escape. In murine model, immune exhaustion results in persistent viral replication and generation of functionally defective memory T cell, including chemotactism defect. 4 In our patient, we hypothesize that chemotactism defect has been responsible of the persistence of tissue infection (mainly the lung), despite the presence of IFN-γ secretion by EBV CTL. Our results are consistent with the findings described in murine models. In humans, little is known about immune exhaustion and most reports concern HIV disease. 5, 6 This study is the first to document full activation of the immune system with evidence of immune exhaustion in human viral disease after CBT.
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